Senti Bio reports Q1 2025 net loss $14.1M; SENTI-202 Phase 1 shows 4 of 7 cCR with MRD negativity

Senti Biosciences, Inc.

2025-Q1 EPS reported -$1.41

Net loss of $14.1M ($1.41 per share) for Q1 2025; cash and equivalents $33.8M as of March 31.
Phase 1 SENTI-202 data: 4 of 7 patients achieved composite CR (3 CR, 1 CRh); all MRD negative by local standard of care.
Preliminary RP2D set at 1.5 x 10^9 CAR NK cells given on Days 0,7,14 in 28-day cycles after lymphodepletion.
Responses ongoing from 4+ to 8+ months; 3 patients received bone marrow transplant after SENTI-202.
R&D expenses $9.3M (up $0.5M YoY); G&A expenses $7.1M (down $0.4M YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.